LiLii is a Software-as-a-Service (SaaS) platform that leverages LiVeritas’ artificial intelligence (AI) technology to simplify workflows and improve productivity for drug developers at all phases of development
LiVeritas rolls out AI-powered LiLii platform. (Credit: Michal Jarmoluk from Pixabay)
LiVeritas Biosciences, a hybrid life science data and analytics company, has announced the beta testing of the LiLii platform, its new-generation, fully integrated laboratory ecosystem.
LiLii is a Software-as-a-Service (SaaS) platform intended for use in analytical laboratory operations and project management.
The platform leverages the company’s artificial intelligence (AI) technology to simplify workflows and improve productivity for drug developers at all phases of development.
LiLii analytical tools, together with an AI biopharma knowledge base, will help drug developers with data processing, analysis, and reporting through a single intuitive interface.
LiVeritas Biosciences co-founder and CEO Lieza Danan said: “The LiLii platform is the realisation of a holistic vision developed while I led mass spectrometry and analytical development functions in biopharma.
“Instead of fragmented tools of the past, I needed optimised, automated workflows to serve the urgent needs of various drug development functions.
“Our founding team has complimentary backgrounds in chemistry, computer engineering, and 100+ years of analytical testing experience.
“Together, we have created a scalable, tech-enabled platform that provides end-users with the power to rapidly generate consistent, superior quality data for actionable insights that will unlock value in Biopharma Industry 4.0 and beyond.”
LiLii platform prevents the need for multiple software packages, while helping increase the speed of drug development through rapid generation of high-quality data and analytics.
The platform unifies project management, customer relationship management (CRM), document management and communications capabilities.
It rapidly translates the sample information into scientifically useful information, reducing the time required for project initiation, while minimising the risk of errors with manual onboarding.
The LiLii platform enables drug developers to process sample data faster than conventional methods, with improved data integrity cost-effective outcomes and reduced risk.
With a modular and expandable architecture, the platform can be integrated into any analytical testing laboratory, and its AI capabilities enhance endusers analytical skill sets.
LiVeritas co-founder and technology development VP Nina Cortina said: “Instead of clients communicating with LiVeritas through multiple separate channels, the LiLii platform centralises communications under a single point of digital interaction.
“Our platform serves as an information aggregator, ensuring information is consistent between the client and LiVeritas with complete transparency and traceability, enabling our team to carry out analytical services more rapidly, efficiently, and optimally effectively.”